Compare CAAS & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAAS | CDXS |
|---|---|---|
| Founded | N/A | 2002 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Major Chemicals |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.6M | 141.8M |
| IPO Year | N/A | 2010 |
| Metric | CAAS | CDXS |
|---|---|---|
| Price | $4.52 | $1.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.7K | ★ 1.1M |
| Earning Date | 11-12-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.68 | N/A |
| EPS | ★ 1.11 | N/A |
| Revenue | ★ $725,260,000.00 | $52,932,000.00 |
| Revenue This Year | N/A | $15.64 |
| Revenue Next Year | N/A | $5.23 |
| P/E Ratio | $4.04 | ★ N/A |
| Revenue Growth | ★ 16.72 | N/A |
| 52 Week Low | $3.50 | $1.52 |
| 52 Week High | $5.37 | $5.43 |
| Indicator | CAAS | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 68.95 | 47.87 |
| Support Level | $4.24 | $1.58 |
| Resistance Level | $4.60 | $1.74 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 93.33 | 61.76 |
China Automotive Systems Inc is a holding company. The firm through its subsidiary is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series, models of power steering including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.